Case Summary:

One of the few leading experts to improve the delivery of mRNA therapeutics to increase the effectiveness of gene therapies for incurable conditions, our client achieved a consistent and remarkable record of success and influence in these areas of study. He approached the North America Immigration Law Group to help him build an influential I-140 NIW (National Interest Waiver) petition, establishing that he is well-known for:

• Formulating and characterizing novel nanoparticles, conducting in vivo imaging, developing advanced animal models to test his therapeutics, and publishing original nanomedicine research in peer-reviewed journals and conference proceedings.
• His lipid-based encapsulation of anti-cancer drugs limits the side effects of chemotherapy, which enhances the safety and health outcomes of cancer patients worldwide.

His splendid credentials ensured that we countersigned the client-attorney relationship agreement and proceeded with preparing a strong petition dossier to achieve the national interest waiver for our noteworthy client. We highlighted the following important aspects while filing his NIW case:

• Peer-review experience is considered to be a widely accepted method for research validation with publishers relying on the peer-review process to uphold the quality and validity of individual articles and the journals that publish them. Therefore, he evaluated the work of his peers no fewer than 26 times.
• His research has resulted in 9 peer-reviewed journal articles (6 of them first-authored) and 2 published patents, published in the top journals of his field, reflecting his peers’ recognition of the value of this research.
• His publications attracted 110 citations from a wide audience hailing from well-known international institutions both in the United States and abroad.

Not only did we assist him in devising this successful case but also made sure to compile all the new information provided by our client to be incorporated in his petition to meet the requirements.

Moreover, his work was funded by:

• the Japan Science and Technology Agency, the Japan Agency for Medical Research and Development, and the Japan Society for the Promotion of Science. This funding supports projects that commercialize new technologies, provide foundations of social development, and lengthen the lives of people worldwide.

Therefore, our client’s research addresses these goals by developing novel nanomedicine delivery systems to improve the efficacy of existing gene editing tools and improving vital therapeutics for brain diseases that shorten lives, such as Alzheimer’s.

Furthermore, he even got 4 recommendation letters in his favor, one excerpt out of the same is mentioned below:

“[Client’s] novel lipid pharmaceutical excipient is a substantial discovery for the pharmaceutical industry as it promises improved absorption of drugs which would allow for dose reduction of active ingredients…This presents a massive benefit to the American public and allows for cheaper and more accessible treatments.”

Overall, we are glad that we were able to prove to the USCIS that our client’s research would be beneficial for the entire nation as his proposed endeavor of improving the delivery of mRNA therapeutics to increase the effectiveness of gene therapies for incurable conditions directly addresses critical issues related to high prescription drug costs, the sustainability of the biopharmaceutical industry in the U.S., vaccine efficacy, and reducing undesirable drug side-effects from anti-cancer drugs. Thus he received his NIW approval despite a long wait.

We truly thank him for his constant cooperation and kind support throughout the adjudication process and wish him good luck in his upcoming endeavors.